

NIOSH Diacetyl Public Presentation – August 25, 2011 – Washington DC

Risk Assessment for diacetyl airborne exposures based on human studies: microwave popcorn workers

Robert M. Park
Stephen J. Gilbert
Christine W. Sofge

Risk Evaluation Branch
Education and Information Division
National Institute for Occupational Safety and Health

Introduction

NIOSH did 6 HHEs in MW popcorn plant populations

-> 4 investigated -> 3 analyzed -> 1 basis for risk assessment

Cross-sectional designs: all but one HHEs did survey at one point in time; plant used for RA did 8 in surveys over 32 months

Primary plant: ~360 active employees participated in 1 or more surveys


Two approaches: 1) loss of breathing capacity in surveyed population
2) onset of cases of pulmonary impairment

Diacetyl air-sampling results (corrected) at four HHE study sites in major process areas

Personal Samples

Site	Mixing		Production		Quality Control		Maintenance	
	n	Mean	n	Mean	n	Mean	n	Mean
N	1	0.79	7	0.740	2	0.250	2	0.160
K	5	0.31	7	0.040	3	0.003	3	0.020
L	10	1.15	36	0.028	5	0.034	6	0.014
G	25	2.36	112	0.490	20	0.370	17	0.080

Inherent variability of FEV₁ as observed in NHANES III population



Regression models for percent of predicted FEV₁ comparing diacetyl exposure metrics at Site G

	R ²	Intercept	t-statistic (1df) for Exposure Metric	P value
Avg(DA)	0.128	94.99	2.41	0.0167
Cum(DA ^{2.0})	0.142	94.62	3.41	0.0007
(Cum(DA)) ^{2.0}	0.148	94.76	3.76	0.0002
Duration	0.161	97.17	4.43	9×10 ⁻⁶
Cum(DA)	0.169	95.95	4.83	10 ⁻⁶
Cum(DA ^{0.5})	0.172	96.38	4.95	7×10 ⁻⁷
(Cum(DA)) ^{0.5}	0.174	97.34	5.04	4×10 ⁻⁷
(Cum(DA ^{0.5})) ^{0.5}	0.176	98.25	5.16	2×10 ⁻⁷

Cum(DA) = cumulative exposure = \sum_i (DA) over time

Full regression models of percent of predicted FEV₁ for selected DA exposure metrics at Site G

	Cum(DA)		(Cum(DA)) ^{0.5}		Cum(DA ^{0.5})	
	R ² = 0.169		R ² = 0.174		R ² = 0.172	
	β	P	β	P	β	P
intercept	95.95	—	97.34	—	96.38	—
female	-0.386	0.82	0.092	0.96	-0.306	0.86
hispanic	1.99	0.40	1.42	0.55	1.70	0.47
black	8.58	0.45	7.78	0.49	8.30	0.46
smoke_ever	7.29	0.0020	6.86	0.0038	6.88	0.004
packyrs	-0.571	0.0008	-0.562	0.0009	-0.560	0.0009
packyr2	0.0024	0.36	0.0024	0.34	0.0025	0.32
DA exposure	-0.500	10⁻⁶	-2.77	4×10⁻⁷	-0.843	7×10⁻⁷

Regression models for percent of predicted FEV₁ at three HHE study sites comparing diacetyl exposure metrics

Site	Cum(DA)			(Cum(DA)) ^{0.5}		
	β	R ²	P	β	R ²	P
K	-7.77	0.322	< 10 ⁻⁷	-14.3	0.286	10 ⁻⁶
L	-3.56	0.138	0.0012	-9.15	0.146	0.0004
G	-0.50	0.169	10 ⁻⁶	-2.77	0.174	< 10 ⁻⁶

Regression models for FEV₁ /FVC at three HHE study sites comparing diacetyl exposure metrics

Site	Cum(DA)			(Cum(DA)) ^{0.5}		
	β	R ²	P	β	R ²	P
K	-4.30	0.449	< 10 ⁻⁷	-8.24	0.420	< 10 ⁻⁷
L	-2.16	0.213	< 10 ⁻⁵	-5.26	0.212	< 10 ⁻⁵
G	-0.16	0.342	0.0024	-0.98	0.346	0.0007

Two definitions of case for onset of pulmonary impairment

- 1) $FEV_1 < \text{Lower Limit of Normal (LLofN)}$ - defined from NHANES equations.
- 2) $FEV_1 < \text{LLofN}$ **and** $FEV_1/FVC < \text{LLofN}$

Date of onset defined:

average date when continuing symptoms began (from questionnaire)

non-symptomatic cases excluded

Incidence of new cases (definition 2: FEV₁ and FEV₁/FVC < LLoFN) in Poisson regression with log-linear models

Model	Metric	Effect	RR	Δ -2lnL	Wald P
		Estimate	5yr @ 2 ppm		
1	Duration	-0.085	-	0.0	0.23
2	Cum(DA)	0.012	-	-	0.60
3	Duration	-0.300			0.023
	Cum(DA)	0.090	2.46	5.31	0.16
4	Duration	-0.555			0.036
	Cum(DA ^{0.5})	0.316	9.37	5.50	0.041
5	Duration	-0.411			0.0085
	(Cum(DA)) ^{0.5}	0.804	12.7	8.76	0.005
6	Duration	-0.088			0.24
	Avg(DA)	0.468	2.55	8.75	0.001

Predicted rate ratios relative to a fixed baseline rate

Case definition 2: Rate Ratio (relative to baseline: 0.0046)

		Cumulative Diacetyl Exposure (ppm-yrs)					All
		< 0.5	0.5<2.0	2.0<3.0	3.0<5.0	≥ 5.0	
Duration (yrs)	< 0.5	5.39	6.54	1.91	1.15	—	5.67
	0.5 <1.0	4.39	6.22	6.57	7.70	5.39	5.59
	1.0<2.0	4.26	3.72	7.00	7.63	6.98	6.22
	2.0<4.0	2.54	4.43	4.70	5.61	7.74	6.63
	≥ 4.0	0.83	0.85	3.15	1.57	5.11	4.33
	All	4.22	4.89	5.85	6.17	5.85	5.35

Linear relative-rate model to describe incidence of cases with apparent declining susceptibility or response to exposure

$$\text{rate} = \{\exp(\alpha + \beta \text{smoker} + \gamma \text{sex} + \delta(\text{age}-40) + \varepsilon(\text{age}-40)^2)\} \times \{1 + \theta \text{packyrs} + \sigma \mathbf{HRX} + \mu \text{cumDA}\}$$

$$\mathbf{HRX} = [\text{DA}]^2 \exp(-0.693 \text{dur} / \mathbf{2.0}) \quad - \text{ for half-life} = \mathbf{2.0} \text{ yr}$$

2 yr half-life produces better fit than 1 yr

$[\text{DA}]^2$ fits better than $[\text{DA}]$

Incidence of new cases (defn2: FEV₁, FEV₁/FVC < LLoFN) Poisson regression with linear relative-rate model


Parameter	Estimate	RR	LRT	P value
intercept	-15.5			
smoke_ever	-0.68	0.51		
Ind:female	0.97	2.63		
age-40	0.041	1.04		
(age-40) ²	-0.002	0.998		
packyrs	17.7	18.7		
cum(DA)	12.3	13.3	2.19	0.07
HRX (t-half =2 yr)	69.8	70.8	7.78	0.0026

Rate = {exp(α + β smoker + γ sex + δ (age-40) + ϵ (age-40)²)}{1 + θ packyrs + σ HRX + μ cumDA}

RR - @ 1 pack-yr, 1 ppm at day 1 (HRX), 1 ppm-yr (cum(DA)); p value: one-tailed

HRX = [DA]²exp(-0.693dur/2) – for half-life = 2.0 yr

BMD paradigm: assumes uniform response – susceptibility – and known distribution



Benchmark dose for pulmonary impairment based on cum(DA) metric and 45 yr work-life

Percent of predicted FEV₁

DA (ppm)	cum. exp. (ppm-yrs)	Model-predicted ppFEV ₁	Excess Prevalence per 1000	
			< 60% of predicted	< 5 th percentile
1	45.0	77.5	126.7	366.8
0.5	22.5	88.8	27.9	126.7
0.2	9.00	95.5	6.4	37.2
0.1	4.50	97.8	2.7	16.6
0.05	2.25	98.9	1.2	7.8
0.02	0.90	99.6	0.5	3.0
0.01	0.45	99.8	0.2	1.5
0.005	0.225	99.89	0.1	0.7
0.002	0.090	99.96	0.0	0.3
0.001	0.045	99.98	0.0	0.1
0.0005	0.0225	99.99	0.0	0.1
0.0002	0.0090	100.00	0.0	0.0

Empirical benchmark doses for FEV₁ and FEV₁/FVC for 45 yr worklife using NHANES population

DA (ppm)	Excess prevalence (per 1000)	
	FEV ₁	FEV ₁ /FVC
1	532.5	220.5
0.5	202.9	82.4
0.2	58.7	27.4
0.1	25.7	12.1
0.05	12.3	6.8
0.02	4.8	3.2
0.01	2.5	2.1
0.005	1.3	1.0
0.004	0.4	0.4
0.003	0.2	0.3
0.002	0.2	0.2
0.001	0.1	0.1
0.0005	0.1	0.1

Excess lifetime risk for becoming a case (definition 2) based on life-table (BEIR IV) analysis for 45 yr work-life

DA (ppm)	per 1000
1	248.8
0.5	140.7
0.2	60.8
0.1	31.2
0.05	15.8
0.02	6.4
0.01	3.2
0.005	1.6
0.002	0.6
0.001	0.3
0.0005	0.2
0.0002	0.1
0.0001	0.0

Excess lifetime risk of mortality associated with declining FEV₁

- Published literature indicates 1% loss of FEV₁ is associated with ~ 1.5% increase in mortality rate independent of other risk factors such as age, gender, race, BMI.

- This is not specific to bronchiolitis obliterans, rather a generic effect.

- Using exposure response for FEV₁ based on cum(DA), estimate excess mortality with lifetable method:

DA (ppm)	Per 1000
1.0	221.6
0.5	121.1
0.2	51.2
0.1	26.1
0.05	13.2
0.02	5.30
0.01	2.65
0.005	1.33
0.002	0.53
0.001	0.27
0.0005	0.13
0.0002	0.05

Summary of risk assessment findings in range 0.05 – 0.001 ppm diacetyl

DA		Method (per 1000)			
		BMD Excess Prevalence		Life-table Excess Lifetime Risk	
		ppm	ppb	Impairment FEV ₁ (<LLofN)	FEV ₁ /FVC (<LLofN)
0.05	50	12.3	6.8	15.8	13.2
0.02	20	4.8	3.2	6.4	5.3
0.01	10	2.5	2.1	3.2	2.7
0.005	5	1.3	1.0	1.6	1.3
0.004	4	1.1	0.8	1.3	1.1
0.003	3	0.6	0.6	1.0	0.8
0.002	2	0.4	0.4	0.6	0.5
0.001	1	0.2	0.3	0.3	0.3

Summary of risk assessment findings by level of lifetime risk for diacetyl

Lifetime Risk	Method			
	BMD Excess Prevalence (ppb)		Life-table Excess Lifetime Risk (ppb)	
	Impairment		Case onset (definition 2)	Mortality
	FEV ₁ (LLOfN)	FEV ₁ /FVC (LLOfN)		
1/10	300	600	300	400
1/100	40	80	30	40
1/1000	4	5	3	4
1/10000	0.4	0.5	0.2	0.4
1/100000	0.04	0.05	0.02	0.04

Issues addressed in NIOSH risk assessment for diacetyl

- Exposure assessment: unusually extensive with declining levels described
- Definition of impairment: analyses of outcomes that would encompass both obstructive and restrictive disease produced concordant estimates of risk as did three risk assessment methods
- Cross-sectional study limitations: affected workers leaving employment likely has resulted in under-estimation of exposure response, as did exclusion of asymptomatic cases in the incidence analysis
- Apparent unknown variability in susceptibility required an ad hoc statistical model specification which accommodated higher risk in a declining subpopulation, or, generally declining susceptibility with exposure duration

...Issues addressed

- 45 yr exposure in a single hypothetical population would under-estimate the impact of variable susceptibility (survivor bias)
- Low dose extrapolation: career-average DA exposures at Site G were below 0.01 ppm in 13% of workers; proposed REL is only factor of 2 below 0.01 ppm.